Finances, Heparin Concerns

ROVI's financial position remains solid with a net debt of EUR14.9 million and plans to propose a dividend payout of 35 % of consolidated net profit. The company maintains its commitment to reaching EUR700 million in CDMO sales by 2030. However, there are concerns regarding the heparin division due to lower bemiparin sales driven by high inventory levels from international partners and increased pricing pressure from Chinese players.